Berkeley Lights, Inc.

Bruker Cellular Analysis, Inc.

Phenomex Inc.

Xiaohua Wang

Volker L S Kurz

Kevin T Chapman

J Tanner Nevill

Andrew W McFarland

Randall D Lowe, Jr

Troy A Lionberger

Kristin G Beaumont

Mark P White

Jason M McEwen

Gang F Wang

Gregory G Lavieu

Peter J Beemiller

Guido K Stadler

Eric D Hobbs

Keith J Breinlinger

Daniele Malleo

Alexander J Mastroianni

Xiao Guan Radstrom

Aathavan Karunakaran

Minha Park

Paul M Lebel

Brandon R Bruhn

Peggy A Radel

Yelena Bronevetsky

Nan-Linda Ding

Kai W Szeto

George L Fox

Randall D Lowe

Eric Sackmann

Annamaria Mocciaro

Xiao Guan

Ravi K Ramenani

Kevin D Loutherback

Christine E Sun

Eric K Sackmann

Jason M Mcewen

Andrew W Mcfarland

Volker Ls Kurz

Jason C Briggs

Adrienne T Higa

Hariharasudhan Chirra Dinakar

Jr Randall D Lowe

In situ-generated microfluidic isolation structures incorporating a solidified polymer network, methods of preparation and use, compositions and kits therefor are described. The ability to introduce in real time, a variety of isolating structures including pens and barriers offers improved methods of micro-object manipulation in microfluidic devices. The in situ-generated isolation structures may be permanently or temporarily installed.

In situ-generated microfluidic isolation structures, kits and methods of use thereof

A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Apparatuses and methods are described for the use of optically driven bubble, convective and displacing fluidic flow to provide motive force in microfluidic devices. Alternative motive modalities are useful to selectively dislodge and displace micro-objects, including biological cells, from a variety of locations within the enclosure of a microfluidic device.

Microfluidic devices for optically-driven convection and displacement, kits and methods thereof

Methods of sorting T lymphocytes in a microfluidic device are provided. The methods can include flowing a fluid sample comprising T lymphocytes through a region of a microfluidic device that contains an array of posts. The array of posts can be configured to have a critical size (D) that separates activated T lymphocytes from na&#xef;ve T lymphocytes. Also provided are microfluidic devices having an array of posts configured to separate activated T lymphocytes from na&#xef;ve T lymphocytes, compositions enriched for T lymphocytes, particularly activated T lymphocytes that are known to be reactive to an antigen of interest, and methods of treating subjects suffering from a pathogenic disorder or cancer by administering such compositions.

Sorting of T lymphocytes in a microfluidic device

In situ-generated microfluidic capture structures incorporating a solidified polymer network, methods of preparation and use, compositions and kits therefor are described. Microfluidic capture structures may be advantageously used for assays performed within the microfluidic environment, providing flexibility in assaying micro-objects such as biological cells. Assay reagents and analytes may be incorporated within the microfluidic capture structures.

In situ-generated microfluidic assay structures, related kits, and methods of use thereof

The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.

Tumor infiltrating cells engineered to express a pro-inflammatory polypeptide

Functional assays using reporter cell assays are described which probe the activity of at least one cell of interest. The ability to probe at least one cell is provided by using the microfluidic methods, devices and kits described herein. Assays combining both reporter cell signaling as well as binding assay signaling for at least one cell is also described herein.

Microfluidic reporter cell assay methods and kits thereof

Growing community of inventors

Albany, CA, United States of America

Xiaohua Wang